- The company produced solid Q4 result and 2019 outlook, without exceeding expectations. The company introduced a second sensible acquisition increasing its wallet space of its customers offering them another product line. The company is a solid long-term prospect, although the shares are not cheap and there is not that much room for further valuation multiple expansion.
SHU Portfolio: BioLife Solutions Marches On
March 29th, 2019 · No Comments